NASDAQ:WVE

Wave Life Sciences Competitors

$6.26
-0.18 (-2.80 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.25
Now: $6.26
$6.60
50-Day Range
$5.61
MA: $8.37
$10.71
52-Week Range
$4.82
Now: $6.26
$19.98
Volume687,033 shs
Average Volume853,865 shs
Market Capitalization$306.72 million
P/E RatioN/A
Dividend YieldN/A
Beta0.35

Competitors

Wave Life Sciences (NASDAQ:WVE) Vs. PHAT, INVA, MRSN, NKTX, CDMO, and YMAB

Should you be buying WVE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Wave Life Sciences, including Phathom Pharmaceuticals (PHAT), Innoviva (INVA), Mersana Therapeutics (MRSN), Nkarta (NKTX), Avid Bioservices (CDMO), and Y-mAbs Therapeutics (YMAB).

Wave Life Sciences (NASDAQ:WVE) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Earnings & Valuation

This table compares Wave Life Sciences and Phathom Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Wave Life Sciences$15.98 million19.19$-193,640,000.00($5.72)-1.09
Phathom PharmaceuticalsN/AN/A$-255,130,000.00($13.98)-2.74

Wave Life Sciences has higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Wave Life Sciences, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Wave Life Sciences has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Wave Life Sciences and Phathom Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Wave Life Sciences02202.50
Phathom Pharmaceuticals10402.60

Wave Life Sciences presently has a consensus price target of $11.80, suggesting a potential upside of 88.50%. Phathom Pharmaceuticals has a consensus price target of $53.00, suggesting a potential upside of 38.20%. Given Wave Life Sciences' higher possible upside, equities analysts plainly believe Wave Life Sciences is more favorable than Phathom Pharmaceuticals.

Profitability

This table compares Wave Life Sciences and Phathom Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Wave Life Sciences-1,562.01%-401.32%-72.82%
Phathom PharmaceuticalsN/A-88.73%-69.04%

Institutional and Insider Ownership

80.7% of Wave Life Sciences shares are held by institutional investors. Comparatively, 73.8% of Phathom Pharmaceuticals shares are held by institutional investors. 38.2% of Wave Life Sciences shares are held by insiders. Comparatively, 39.8% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Phathom Pharmaceuticals beats Wave Life Sciences on 7 of the 13 factors compared between the two stocks.

Wave Life Sciences (NASDAQ:WVE) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.

Institutional & Insider Ownership

80.7% of Wave Life Sciences shares are owned by institutional investors. Comparatively, 71.5% of Innoviva shares are owned by institutional investors. 38.2% of Wave Life Sciences shares are owned by insiders. Comparatively, 0.3% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Wave Life Sciences and Innoviva's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Wave Life Sciences$15.98 million19.19$-193,640,000.00($5.72)-1.09
Innoviva$261.02 million4.56$157.29 million$1.438.22

Innoviva has higher revenue and earnings than Wave Life Sciences. Wave Life Sciences is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Wave Life Sciences has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Wave Life Sciences and Innoviva, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Wave Life Sciences02202.50
Innoviva10001.00

Wave Life Sciences currently has a consensus price target of $11.80, suggesting a potential upside of 88.50%. Innoviva has a consensus price target of $10.00, suggesting a potential downside of 14.89%. Given Wave Life Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Wave Life Sciences is more favorable than Innoviva.

Profitability

This table compares Wave Life Sciences and Innoviva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Wave Life Sciences-1,562.01%-401.32%-72.82%
Innoviva67.16%53.99%28.92%

Summary

Innoviva beats Wave Life Sciences on 8 of the 14 factors compared between the two stocks.

Wave Life Sciences (NASDAQ:WVE) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.

Institutional and Insider Ownership

80.7% of Wave Life Sciences shares are owned by institutional investors. 38.2% of Wave Life Sciences shares are owned by company insiders. Comparatively, 5.3% of Mersana Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Wave Life Sciences and Mersana Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Wave Life Sciences$15.98 million19.19$-193,640,000.00($5.72)-1.09
Mersana Therapeutics$42.12 million28.10$-28,210,000.00($0.65)-26.37

Mersana Therapeutics has higher revenue and earnings than Wave Life Sciences. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Wave Life Sciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Wave Life Sciences has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 2.54, indicating that its stock price is 154% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Wave Life Sciences and Mersana Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Wave Life Sciences02202.50
Mersana Therapeutics02502.71

Wave Life Sciences currently has a consensus price target of $11.80, indicating a potential upside of 88.50%. Mersana Therapeutics has a consensus price target of $26.1667, indicating a potential upside of 52.66%. Given Wave Life Sciences' higher possible upside, analysts clearly believe Wave Life Sciences is more favorable than Mersana Therapeutics.

Profitability

This table compares Wave Life Sciences and Mersana Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Wave Life Sciences-1,562.01%-401.32%-72.82%
Mersana Therapeutics-8,772.91%-45.16%-37.53%

Summary

Mersana Therapeutics beats Wave Life Sciences on 9 of the 14 factors compared between the two stocks.

Wave Life Sciences (NASDAQ:WVE) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.

Institutional and Insider Ownership

80.7% of Wave Life Sciences shares are owned by institutional investors. Comparatively, 77.1% of Nkarta shares are owned by institutional investors. 38.2% of Wave Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Wave Life Sciences and Nkarta's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Wave Life Sciences-1,562.01%-401.32%-72.82%
NkartaN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for Wave Life Sciences and Nkarta, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Wave Life Sciences02202.50
Nkarta00503.00

Wave Life Sciences currently has a consensus price target of $11.80, indicating a potential upside of 88.50%. Nkarta has a consensus price target of $59.00, indicating a potential upside of 63.98%. Given Wave Life Sciences' higher possible upside, analysts clearly believe Wave Life Sciences is more favorable than Nkarta.

Earnings & Valuation

This table compares Wave Life Sciences and Nkarta's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Wave Life Sciences$15.98 million19.19$-193,640,000.00($5.72)-1.09
NkartaN/AN/AN/AN/AN/A

Nkarta has lower revenue, but higher earnings than Wave Life Sciences.

Summary

Nkarta beats Wave Life Sciences on 5 of the 9 factors compared between the two stocks.

Avid Bioservices (NASDAQ:CDMO) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Risk & Volatility

Avid Bioservices has a beta of 2.36, suggesting that its share price is 136% more volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500.

Institutional and Insider Ownership

58.2% of Avid Bioservices shares are owned by institutional investors. Comparatively, 80.7% of Wave Life Sciences shares are owned by institutional investors. 1.7% of Avid Bioservices shares are owned by insiders. Comparatively, 38.2% of Wave Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Avid Bioservices and Wave Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Avid Bioservices0.20%0.31%0.13%
Wave Life Sciences-1,562.01%-401.32%-72.82%

Analyst Recommendations

This is a summary of current ratings and price targets for Avid Bioservices and Wave Life Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Avid Bioservices00303.00
Wave Life Sciences02202.50

Avid Bioservices presently has a consensus target price of $17.3333, indicating a potential downside of 9.86%. Wave Life Sciences has a consensus target price of $11.80, indicating a potential upside of 88.50%. Given Wave Life Sciences' higher probable upside, analysts plainly believe Wave Life Sciences is more favorable than Avid Bioservices.

Earnings and Valuation

This table compares Avid Bioservices and Wave Life Sciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avid Bioservices$59.70 million19.59$-10,470,000.00($0.27)-71.22
Wave Life Sciences$15.98 million19.19$-193,640,000.00($5.72)-1.09

Avid Bioservices has higher revenue and earnings than Wave Life Sciences. Avid Bioservices is trading at a lower price-to-earnings ratio than Wave Life Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Avid Bioservices beats Wave Life Sciences on 10 of the 14 factors compared between the two stocks.

Y-mAbs Therapeutics (NASDAQ:YMAB) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

Analyst Recommendations

This is a summary of current ratings and price targets for Y-mAbs Therapeutics and Wave Life Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Y-mAbs Therapeutics02602.75
Wave Life Sciences02202.50

Y-mAbs Therapeutics presently has a consensus target price of $58.1429, indicating a potential upside of 117.03%. Wave Life Sciences has a consensus target price of $11.80, indicating a potential upside of 88.50%. Given Y-mAbs Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Y-mAbs Therapeutics is more favorable than Wave Life Sciences.

Profitability

This table compares Y-mAbs Therapeutics and Wave Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Y-mAbs TherapeuticsN/A-74.98%-66.70%
Wave Life Sciences-1,562.01%-401.32%-72.82%

Risk & Volatility

Y-mAbs Therapeutics has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500.

Earnings and Valuation

This table compares Y-mAbs Therapeutics and Wave Life Sciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Y-mAbs TherapeuticsN/AN/A$-81,030,000.00($2.30)-11.65
Wave Life Sciences$15.98 million19.19$-193,640,000.00($5.72)-1.09

Y-mAbs Therapeutics has higher earnings, but lower revenue than Wave Life Sciences. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Wave Life Sciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

53.2% of Y-mAbs Therapeutics shares are owned by institutional investors. Comparatively, 80.7% of Wave Life Sciences shares are owned by institutional investors. 38.4% of Y-mAbs Therapeutics shares are owned by insiders. Comparatively, 38.2% of Wave Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Y-mAbs Therapeutics beats Wave Life Sciences on 10 of the 13 factors compared between the two stocks.


Wave Life Sciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.35-1.6%$1.20 billionN/A-2.74
Innoviva logo
INVA
Innoviva
1.4$11.75-1.0%$1.19 billion$261.02 million5.99
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$17.14-5.7%$1.18 billion$42.12 million-12.70Unusual Options Activity
News Coverage
NKTX
Nkarta
1.8$35.98-1.2%$1.18 billionN/A0.00Increase in Short Interest
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.23-0.1%$1.17 billion$59.70 million-192.30
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.79-4.5%$1.17 billionN/A-9.02Insider Selling
Increase in Short Interest
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.14-1.8%$1.15 billion$35.22 million-7.40
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$25.99-1.6%$1.14 billion$230,000.00-12.09
MannKind logo
MNKD
MannKind
1.4$4.56-7.7%$1.14 billion$63.04 million-21.71Increase in Short Interest
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$16.24-3.3%$1.11 billionN/A-6.85
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$23.08-5.2%$1.10 billionN/A-8.52
Omeros logo
OMER
Omeros
1.4$17.56-0.4%$1.09 billion$111.81 million-7.38
Zogenix logo
ZGNX
Zogenix
1.7$19.43-1.7%$1.08 billion$3.65 million-2.04
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$30.23-0.1%$1.08 billion$57.05 million0.00
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$10.24-1.6%$1.05 billion$120,000.00-3.79Analyst Upgrade
News Coverage
Gap Down
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$39.92-1.2%$1.05 billion$20.79 million-13.77Analyst Upgrade
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$21.68-5.0%$1.05 billion$1.52 million-11.53Increase in Short Interest
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$20.75-0.5%$1.04 billionN/A-6.83Increase in Short Interest
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$24.70-1.7%$1.04 billionN/A-8.52
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.65-2.4%$1.02 billion$122.47 million-27.83Analyst Downgrade
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.25-0.2%$980.99 million$800.40 million22.88News Coverage
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$25.30-20.0%$976.05 millionN/A0.00High Trading Volume
Increase in Short Interest
Lockup Expiration
News Coverage
Prothena logo
PRTA
Prothena
2.1$23.96-2.5%$958.54 million$810,000.00-9.36Increase in Short Interest
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.31-3.3%$949.57 millionN/A-12.59Analyst Upgrade
Radius Health logo
RDUS
Radius Health
1.3$19.67-3.9%$922.41 million$173.32 million-8.06
Affimed logo
AFMD
Affimed
1.6$10.33-4.3%$912.41 million$23.96 million-17.51Analyst Report
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.45-0.9%$902.83 million$227.19 million45.70
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$26.64-1.7%$899.90 millionN/A-24.67
Annexon logo
ANNX
Annexon
1.9$23.35-1.3%$890.99 millionN/A0.00Increase in Short Interest
Merus logo
MRUS
Merus
1.6$23.22-2.5%$885.31 million$31.13 million-7.56Analyst Report
Analyst Revision
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.16-1.5%$883.02 millionN/A0.00
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$34.95-1.5%$858.83 millionN/A-10.37
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$24.02-4.6%$845.60 million$296.70 million49.02
Epizyme logo
EPZM
Epizyme
1.8$8.22-0.5%$836.67 million$23.80 million-3.69
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$17.40-0.4%$825.33 million$322.36 million124.29
Humanigen logo
HGEN
Humanigen
1.7$15.38-1.1%$822.55 millionN/A0.00Analyst Report
Increase in Short Interest
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.29-7.4%$781.24 millionN/A0.00Increase in Short Interest
Ardelyx logo
ARDX
Ardelyx
1.6$7.84-8.2%$773.65 million$5.28 million-7.76High Trading Volume
Unusual Options Activity
News Coverage
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$10.20-1.0%$765.62 million$40.89 million-3.52
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$27.15-3.5%$758.65 million$148.36 million-7.05
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.19-0.2%$749.20 million$322.07 million-4.94Decrease in Short Interest
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.45-2.0%$742.46 million$150,000.00-4.93
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.89-1.4%$734.07 million$2.22 million-17.00
Chimerix logo
CMRX
Chimerix
1.3$8.37-0.7%$717.13 million$12.52 million-14.68Analyst Report
Increase in Short Interest
Veru logo
VERU
Veru
1.4$9.88-0.5%$710.49 million$42.59 million-35.28Analyst Report
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$21.41-1.1%$706.87 million$252 million-2.19
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$19.48-7.0%$697.56 million$6.83 million-20.08
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$29.96-2.2%$691.78 million$13.80 million-14.47
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$26.95-0.9%$672.97 million$19.56 million-19.39High Trading Volume
Kadmon logo
KDMN
Kadmon
1.8$3.90-7.2%$670.09 million$5.09 million-6.50Analyst Downgrade
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.